DE60113511D1 - Mischung enthaltend einen inhibitor oder suppressor eines gens und ein molekül,dass an ein expressionprodukt dieses gens bindet - Google Patents

Mischung enthaltend einen inhibitor oder suppressor eines gens und ein molekül,dass an ein expressionprodukt dieses gens bindet

Info

Publication number
DE60113511D1
DE60113511D1 DE60113511T DE60113511T DE60113511D1 DE 60113511 D1 DE60113511 D1 DE 60113511D1 DE 60113511 T DE60113511 T DE 60113511T DE 60113511 T DE60113511 T DE 60113511T DE 60113511 D1 DE60113511 D1 DE 60113511D1
Authority
DE
Germany
Prior art keywords
gene
suppressor
inhibitor
molecule
expression product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60113511T
Other languages
English (en)
Other versions
DE60113511T2 (de
Inventor
Karl-Hermann Schlingensiepen
Reimar Schlingensiepen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Original Assignee
Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH filed Critical Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Application granted granted Critical
Publication of DE60113511D1 publication Critical patent/DE60113511D1/de
Publication of DE60113511T2 publication Critical patent/DE60113511T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60113511T 2000-03-11 2001-03-10 Mischung enthaltend einen inhibitor oder suppressor eines gens und ein molekül,dass an ein expressionprodukt dieses gens bindet Expired - Lifetime DE60113511T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00105190 2000-03-11
EP00105190A EP1133988A1 (de) 2000-03-11 2000-03-11 Mischung enthaldend einen Inhibitor oder Suppressor von einen Gens und eine Moleküle bindende des Expressionprodukt des Gens
PCT/EP2001/002694 WO2001068146A2 (en) 2000-03-11 2001-03-10 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene

Publications (2)

Publication Number Publication Date
DE60113511D1 true DE60113511D1 (de) 2006-02-02
DE60113511T2 DE60113511T2 (de) 2006-06-22

Family

ID=8168078

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60113511T Expired - Lifetime DE60113511T2 (de) 2000-03-11 2001-03-10 Mischung enthaltend einen inhibitor oder suppressor eines gens und ein molekül,dass an ein expressionprodukt dieses gens bindet

Country Status (9)

Country Link
US (2) US20030186906A1 (de)
EP (2) EP1133988A1 (de)
JP (1) JP4843177B2 (de)
AT (1) ATE304858T1 (de)
AU (1) AU2001260109A1 (de)
DE (1) DE60113511T2 (de)
ES (1) ES2245364T3 (de)
HK (1) HK1049796B (de)
WO (1) WO2001068146A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242521A1 (en) * 1999-10-25 2004-12-02 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
US20060172925A1 (en) * 1998-10-26 2006-08-03 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
US20030162190A1 (en) * 2001-11-15 2003-08-28 Gorenstein David G. Phosphoromonothioate and phosphorodithioate oligonucleotide aptamer chip for functional proteomics
WO2004016586A2 (en) * 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
CA2749227A1 (en) * 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
EP1635765B1 (de) * 2003-05-23 2013-07-17 Board Of Regents, The University Of Texas System Strukturbasiertes und kombinatorisch ausgewähltes oligonucleosid-phosphorothioat und phosphorodithioat aptamer targeting ap-1 transkriptionsfaktoren
EP1635693A2 (de) * 2003-05-23 2006-03-22 Board Of Regents, The University Of Texas System Screening mit hohem durchsatz von aptamer-bibliotheken für die spezifische bindung an proteine auf viren und anderen erregern
US20050118611A1 (en) * 2003-07-24 2005-06-02 Board Of Regents, The University Of Texas System Thioaptamers enable discovery of physiological pathways and new therapeutic strategies
EP2248895B8 (de) 2003-12-19 2016-09-21 Autotelic LLC Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert
EP1694840A2 (de) * 2003-12-19 2006-08-30 Antisense Pharma GmbH Kombinations-therapie die ein tgf-beta antagonisten mit einem chemotherapeutikum assoziiert
RU2385933C2 (ru) * 2004-02-09 2010-04-10 Реженьон Гмбх Ингибиторы передачи сигнала трансформирующих факторов роста (tgf-r) для лечения расстройств цнс
EP1568383A3 (de) * 2004-02-27 2005-11-16 Antisense Pharma GmbH Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung
JP5650367B2 (ja) * 2004-02-27 2015-01-07 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物
US20050239134A1 (en) * 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
CA2591586A1 (en) 2005-05-05 2006-11-09 Antisense Pharma Gmbh Dosage of oligonucleotides
KR101561652B1 (ko) * 2006-07-18 2015-10-20 녹손 파르마 아게 Sdf-1 결합형 c형 핵산분자
BRPI0815094B8 (pt) * 2007-08-06 2023-04-18 Noxxon Pharma Ag Uso de uma molécula de ácido l-nucleico ligada a sdf-1
DE102007056488A1 (de) * 2007-11-22 2009-07-23 Biontex Laboratories Gmbh Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
AU2011263642B2 (en) 2010-06-11 2014-09-04 Isarna Therapeutics Gmbh Method for selective oligonucleotide modification
US9427458B2 (en) 2010-07-22 2016-08-30 Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet Methods for inhibiting cancer cell proliferation
CN104800858B (zh) * 2015-04-27 2017-11-21 中国医学科学院基础医学研究所 Hsp90抑制肽偶联物及其在肿瘤治疗中的应用
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
WO2017138924A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Compositions and methods for treating pancreatic cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5733523A (en) * 1990-12-10 1998-03-31 Akzo Nobel N.V. Targeted delivery of a therapeutic entity using complementary oligonucleotides
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
DE69429617T2 (de) 1993-04-30 2002-08-22 Biognostik Ges Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
US5683902A (en) * 1994-05-13 1997-11-04 Northern Illinois University Human papilloma virus inhibition by a hairpin ribozyme
US5958769A (en) * 1996-01-18 1999-09-28 Fred Hutchinson Cancer Research Center Compositions and methods for mediating cell cycle progression
US20020165174A1 (en) * 1997-01-31 2002-11-07 Gill Parkash S. Methods and compositions for antisense VEGF oligonucleotides
US6248723B1 (en) * 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
EP0945507A1 (de) * 1998-03-27 1999-09-29 Boehringer Mannheim Gmbh Tumorspezifische Expressionskontrollregion und deren Verwendung
AU5087799A (en) * 1998-07-06 2000-01-24 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
US6900299B1 (en) * 1999-03-11 2005-05-31 University Of South Florida Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection

Also Published As

Publication number Publication date
WO2001068146A3 (en) 2002-01-31
US8703729B2 (en) 2014-04-22
HK1049796B (zh) 2006-01-20
JP2003526684A (ja) 2003-09-09
EP1133988A1 (de) 2001-09-19
DE60113511T2 (de) 2006-06-22
ATE304858T1 (de) 2005-10-15
EP1263446A2 (de) 2002-12-11
US20090285817A1 (en) 2009-11-19
AU2001260109A1 (en) 2001-09-24
HK1049796A1 (en) 2003-05-30
EP1263446B1 (de) 2005-09-21
JP4843177B2 (ja) 2011-12-21
US20030186906A1 (en) 2003-10-02
ES2245364T3 (es) 2006-01-01
WO2001068146A2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
DE60113511D1 (de) Mischung enthaltend einen inhibitor oder suppressor eines gens und ein molekül,dass an ein expressionprodukt dieses gens bindet
HUP0402239A2 (hu) Eltérően oxialkilezett poliolok keverékén alapuló, sugárzásra keményedő uretán-akrilátok
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
CY1109232T1 (el) Νεα καρβαμυλιωμενη ερο και μεθοδος παραγωγης της
ZA200800987B (en) Low pH aerated products
DK1871514T3 (da) Blandeblad med aftageligt slidelement
BR0106649B1 (pt) composição fertilizante contendo enxofre.
WO2004006834A3 (en) Leflunomide analogs for treating rheumatoid arthritis
CY1110537T1 (el) Ενωσεις και μεθοδοι για την αγωγη της δυσλιπιδαιμιας
ATE496109T1 (de) Umsetzungsprodukte von mercaptobenzothiazolen, mercaptothiazolinen und mercaptobenzimidazolen mit epoxiden als schmiermitteladditive
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
MXPA05008933A (es) Composiciones para limpieza de superficies duras.
DE602005009681D1 (de) Haarbehandlungszusammensetzungen mit einem disaccharid; einer disäure und einer ammoniumionen-quelle
MA28354A1 (fr) Nouvelles combinaisons d'un agent anti-emetique et d'un inhibiteur de l'enkephalinase
BR0314241B1 (pt) composto, processos para a preparaÇço do mesmo e para a carbonilaÇço de um composto etilenicamente insaturado, composiÇço, e, uso de um composto ou de uma composiÇço.
AU2003294253A8 (en) Emulsions including surface-modified organic molecules
BRPI0410318A (pt) grãos de cereais enriquecidos com ferro e cálcio e processo para fabricação dos mesmos
WO1999037291A3 (de) Verwendung von substituierten sulfonamiden als antivirale mittel und neue stoffe
BRPI0405791A (pt) Preparados de metal nobre e preparados de lustrina para a serigrafia direta e indireta
ATE466958T1 (de) Klassifizierung von kolonkrebs
DE602004013011D1 (de) Haarbehandlungszusammensetzungen
DK1073623T3 (da) Substituerede aminosyrer som erythropoietin-mimetika

Legal Events

Date Code Title Description
8364 No opposition during term of opposition